Next
Generation Dengue Vaccine, other Solutions Presented
Dengue
remains to be a major public health problem in the Philippines. But it is
reassuring to know that medical science has continued to develop and is working
on real solutions, such as new vaccines and other novel and ingenious solutions
that address the dengue crisis head on.
Affirming that the full might of Japan, one of the healthiest nations in the world, is behind the Philippines in its fight against dengue: Minister Nihei Daisuke, Minister for Economic Affairs, Embassy of Japan in the Philippines.
The
inaugural Dengue Forum titled “Addressing the Mosquito in the Room” held last
Wednesday, 27 September, aimed to amplify the conversation on dengue as a
public health concern in the Philippines. The event was organized by
RiseAboveNow Business Consulting Group (RAN-BCG) and was supported by the
Embassy of Japan in the Philippines and the Department of Health (DOH).
Between
1 January and 9 September of this year, 125,975 dengue cases were reported
across the nation, so far lower compared to cases in the last five years. Since mid-June 2023, 5,000 cases have been
registered on an average every week, according to the Department of Health
(DOH), Philippines.[1] Despite the plateauing dengue cases, the DOH is not
shutting down the possibility of an uptick in cases during the coming the rainy
season.
The
present impact of dengue was described in the recent dengue forum
"Addressing the Mosquito in the Room": The forum gathered a panel of
experts from various relevant fields from both relevant government agencies, as
well as from the private sector. It aimed to raise the alarm on the already
ongoing Dengue Crisis, assess the extent of the burden at this time, map out a
multi-sectoral strategy, but perhaps most importantly, to discuss new
developments globally on newly introduced solutions that can make a real impact
in ending the dengue crisis. This dengue forum was also an opportunity to
establish a robust platform for multi-stakeholder collaboration in addressing
the dengue situation in the country.
In
an official statement, Secretary of the Department of Health (DOH) Teodoro J.
Herbosa, MD, emphasized the urgency of the event, and the importance of a
holistic approach: “This event carries profound significance as it highlights
the importance of a Philippine Collaborative response framework. Dengue is a
self-limiting disease, there is currently no definitive therapy or regimen available,”
he stressed. With the COVID-19 threat now effectively mitigated, dengue now
looms as the one of the most prevalent health concerns in tropical countries
such as the Philippines.
Dr.
Jose Rene de Grano, MHA, president of the Private Hospitals Association of the
Philippines, and pediatrician Dr. Maria Fatima Gualberto of Otsuka Solar Phils.
Inc. of Japan shared that dengue was among the leading causes of
hospitalization in the post COVID-19 era. While Dr. Kim Patrick Tejano of DOH
Disease Prevention and Control Bureau pointed out that dengue was the second
biggest health condition in terms of cost for PhilHealth claims nationwide in
the last year.
The DOH was represented by Ms. Angelica Garcia Supervising Health Program Officer DOH Epidemiology Bureau (Center), who gave a thorough situation report on dengue in the Philippines for the last 3 years. She is flanked by Lo-Anne Villanueva, Country Manager of Takeda Pharmaceuticals (Right) and Ranielle Mendoza -Founding Partner of Rise Above Now (Left).
Meanwhile
Ms. Angelica Garcia of the DOH Epidemiology Bureau, shared the alarming truth,
that statistically, 56% of all dengue fatalities are children 9 years old or
younger. Furthermore, 70% of all dengue cases are people 19 years old or
younger.
Representatives
from Local Government Units where dengue incidence was relatively low namely
Pasig, Caloocan, Quezon City and Baguio shared their best practices in the area
of vector control, or eradication of mosquitoes, emphasizing adherence to the
Five S method of controlling dengue:
Search and destroy
Self-protect
Seek consultation
Support fogging
Sustained Hydration
The fact that Dengue is among the leading causes of hospitalization in the Philippines was pointed out by Dr. Jose Rene de Grano, MHA, President Private Hospitals Association of the Philippines, Inc. (Center). He is flanked by Lo-Anne Villanueva, Country Manager of Takeda Pharmaceuticals (Right) and Ranielle Mendoza -Founding Partner of Rise Above Now (Left).
New hope, a LOT of new hope.
However,
the most promising news came from the medical experts on hand, who shared that
there are in fact new weapons that are available in the war against dengue.
Consultant to the DOH and eminent infectious disease authority, Dr. Rontgene
Solante fully acknowledged the need for stringent vector control, but he
cautioned: “If you focus only on vector control, there is a possibility that it
can also reduce herd immunity.” Dr. Solante then shared that there are in fact
second-generation dengue vaccines, one that is actually already licensed for
use in over 30 countries, including ASEAN neighbors Indonesia and more recently
Thailand.
This vaccine are far more advanced than the
previous generation. They can be administered safely to people whether or not
they have previously had dengue. Numbers are also significantly better than 1st
gen vaccine. Solante shared that the TAK003 vaccine already licensed in over 30
countries are 80.2% effective at preventing dengue infection, compared to just
56% for first gen vaccine, it is also 95.4% effective at preventing severe
dengue, whereas first generation vaccine had only 91% efficacy.
Dr.
Solante shared that the reason behind the superiority of 2nd generation
vaccines was that they were engineered on a dengue virus backbone, whereas the
1st generation was built on a Yellow Fever backbone. This is also the reason
why 2nd gen vaccines are effective even for those who have never had dengue.
Despite
the promise of an effective vaccine, Dr. Solante echoed Secretary Herbosa’s
opinion: “Vector control, environmental control, patient education, awareness,
even updates in the clinical management are all part of what we call an
integrated approach and a vital part of this will be vaccination. So, this is
what we call a comprehensive strategy. You have vaccination, as well as vector
control.”
TAK003
is manufactured by global, research and development-driven pharmaceutical
company Takeda. Takeda was represented at the forum along with three other
Japanese firms and no less than Minister for Economic Affairs at the Embassy of
Japan in the Philippines, Mr. NIHEI Daisuke who affirmed Japan’s commitment to
help ease the global burden of dengue: “We also consider dengue as an
international concern, and we are one with the Philippines in your fight
against this disease.”
TAK003 vaccine was also recently recommended by the World
Health Organization’s Strategic Advisory Group of Experts (SAGE) for
introduction in settings with high dengue disease burden and high transmission
intensity to maximize impact to public health and that the vaccine introduction
should be accompanied by a well-designed communication strategy and community
engagement.[2]
New
vaccines are not the only new development, Dr. Anna Lisa Ong-Lim, Chief of the
Division of Infectious and Tropical Disease at the Philippine General Hospital
shared that there is in fact promising news in the area of developing
antivirals that could both provide immunity and cure already infected patients.
In her presentation, Dr. Ong-Lim shared both the action of the antivirals in
development, as well as what stage of trials they have already shown promise
in.
While
sharing the promise of new developments, Dr. Ong-Lim also talked about simple
yet ingenious best practices that have worked worldwide, such as mosquito nets
that are used to cover entire small villages. She did reiterate the importance
of vaccine, but also pointed out how much more effective these would be if
combined with other tactics: “Of course, we know that vaccines are known to be
the most efficient approach to be able to target big numbers in these kinds of
conditions, but when vaccines are complemented by therapeutic agents, you can
even [have] better control.”
Ultimately
with these new developments, it will be possible to bring dengue numbers down
to insignificant levels. To make dengue vaccination widespread though, will
require that every Filipino learn more about this disease and demand that any
and all means be used to end this crisis.
---------------------------------
About RANBCG
Rise
Above Now Business Consulting Group (RANBCG) is a management, marketing and
capability-building consulting firm based out of the Philippines specializing
in the healthcare industry. RANBCG, with its 50 years of collective healthcare
experience from its roster of consultants, has been a trusted partner of
pharmaceutical companies in conducting medical conventions, virtual engagement
sessions and physical capability-building workshops for healthcare workers. In
2021, RANBCG was the partner of the Department of Health in holding resiliency
workshops for all healthcare professionals amidst the challenges brought about
by the COVID-19 pandemic.